Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
Rhea-AI Summary
Fate Therapeutics (NASDAQ: FATE) said management will participate in five investor conferences in Q2 2026 with scheduled dates and locations listed below.
- April 14 — Needham Virtual Healthcare Conference (virtual)
- May 13 — Bank of America Healthcare Conference, Las Vegas
- May 19 — H.C. Wainwright BioConnect, New York
- June 4 — Jefferies Global Healthcare, New York
- June 10 — Goldman Sachs Global Healthcare, Miami Beach
The company said presentations or fireside chats may occur and live webcasts will be available under Events & Presentations on the company website, with archived replays accessible for 30 days.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – FATE
On the day this news was published, FATE gained 7.63%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.9% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $11M to the company's valuation, bringing the market cap to $149.98M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows peers FBRX and EQ up about 7.35% and 5.00% without news, while other close peers show mixed moves. With the target’s direction unspecified and peer moves mixed, trading appears more stock-specific than broad sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 02 | Inducement RSU grant | Negative | -2.5% | Single new-hire award of 7,260 RSUs vesting over four years. |
| Mar 04 | Inducement RSU grants | Negative | -4.8% | Three new hires granted 50,700 RSUs with four-year vesting schedule. |
| Mar 03 | Conference participation | Positive | +5.8% | Announcement of participation and fireside chat at Leerink healthcare conference. |
| Feb 26 | Earnings and updates | Positive | +5.4% | Reported 2025 financials, $205.1M cash, program progress, and lower expenses. |
| Feb 03 | Inducement awards | Negative | -0.9% | New employee options and RSUs totaling 210,000 shares with staged vesting. |
Recent history shows positive reactions to conferences and earnings updates, while routine inducement equity awards have coincided with modest negative moves.
Over the past few months, Fate Therapeutics has mainly reported employee inducement equity awards, conference participation, and its 2025 financial results. Inducement RSU and option grants on Feb 1, Mar 2, and Apr 1, 2026 saw small negative price reactions. By contrast, the Leerink healthcare conference announcement on Mar 3, 2026 and the Q4 and full-year 2025 update on Feb 26, 2026 were followed by price gains above 5%. Today’s multi-conference participation fits this pattern of visibility-focused, non-fundamental news.
Market Pulse Summary
The stock moved +7.6% in the session following this news. A strong positive reaction aligns with how Fate’s stock previously responded to visibility events such as the Leerink conference and the 2025 results, which saw moves above 5%. This type of multi-conference announcement mainly increases investor engagement rather than altering fundamentals. Investors have also seen recent insider sell-to-cover activity and equity grants, which can temper enthusiasm if momentum fades.
Key Terms
induced pluripotent stem cell (iPSC) medical
cellular immunotherapies medical
AI-generated analysis. Not financial advice.
SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in five upcoming investor conferences in the second quarter of 2026.
25th Annual Needham Virtual Healthcare Conference
Location: Virtual
Date: April 14th
Bank of America Healthcare Conference 2026
Location: Encore at the Wynn - Las Vegas, NV
Date: May 13th
H.C. Wainwright 4th Annual BioConnect Investor Conference
Location: Nasdaq - New York, NY
Date: May 19th
2026 Jeffries Global Healthcare Conference
Location: Marriott Marquis - New York, NY
Date: June 4th
Goldman Sachs 47th Annual Global Healthcare Conference
Location: Loews Miami Beach Hotel - Miami Beach, FL
Date: June10th
The Company may participate in a presentation or a fireside chat at these conferences. When available, a live webcast will be accessible under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. An archived replay of the webcast will be available for 30 days on the Company’s website following the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Ryan Douglas
Fate Therapeutics, Inc.
IR@fatetherapeutics.com
